12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IPP-204106: Phase I/II started

ImmuPharma began a dose-ranging, European Phase I/II trial to evaluate a new formulation of IPP-204106 in about...

Read the full 63 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >